Lexicon Short Term Investments vs Property Plant And Equipment Gross Analysis

LXRX Stock  USD 0.77  0.04  4.94%   
Lexicon Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Lexicon Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lexicon Pharmaceuticals is a good investment. Please check the relationship between Lexicon Pharmaceuticals Short Term Investments and its Property Plant And Equipment Gross accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.

Short Term Investments vs Property Plant And Equipment Gross

Short Term Investments vs Property Plant And Equipment Gross Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lexicon Pharmaceuticals Short Term Investments account and Property Plant And Equipment Gross. At this time, the significance of the direction appears to have almost no relationship.
The correlation between Lexicon Pharmaceuticals' Short Term Investments and Property Plant And Equipment Gross is 0.16. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Property Plant And Equipment Gross in the same time period over historical financial statements of Lexicon Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Lexicon Pharmaceuticals' Short Term Investments and Property Plant And Equipment Gross is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Lexicon Pharmaceuticals are associated (or correlated) with its Property Plant And Equipment Gross. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Gross has no effect on the direction of Short Term Investments i.e., Lexicon Pharmaceuticals' Short Term Investments and Property Plant And Equipment Gross go up and down completely randomly.

Correlation Coefficient

0.16
Relationship DirectionPositive 
Relationship StrengthInsignificant

Short Term Investments

Short Term Investments is an item under the current assets section of Lexicon Pharmaceuticals balance sheet. It contains any investments Lexicon Pharmaceuticals undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Lexicon Pharmaceuticals can easily liquidate in the marketplace.

Property Plant And Equipment Gross

Most indicators from Lexicon Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lexicon Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lexicon Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Lexicon Stock please use our How to Invest in Lexicon Pharmaceuticals guide.At this time, Lexicon Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 145.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (2.71) in 2024.
 2023 2024 (projected)
Extraordinary Items3.6M3.2M
Reconciled Depreciation510K484.5K

Lexicon Pharmaceuticals fundamental ratios Correlations

0.430.230.680.390.360.51-0.57-0.110.470.840.740.130.980.18-0.050.880.720.450.130.780.30.980.330.53-0.39
0.430.390.46-0.2-0.080.240.35-0.340.540.180.21-0.160.390.570.130.50.90.0-0.390.83-0.140.450.110.25-0.23
0.230.390.54-0.12-0.370.60.2-0.310.270.02-0.22-0.20.280.660.210.430.30.07-0.140.42-0.430.35-0.050.14-0.14
0.680.460.540.31-0.020.82-0.37-0.180.860.650.3-0.130.740.160.050.80.580.090.170.8-0.090.730.280.25-0.29
0.39-0.2-0.120.310.20.12-0.550.310.180.480.24-0.20.44-0.35-0.180.35-0.020.380.260.10.120.40.45-0.12-0.25
0.36-0.08-0.37-0.020.2-0.22-0.390.410.020.350.77-0.170.22-0.03-0.460.20.19-0.25-0.120.130.980.190.140.13-0.48
0.510.240.60.820.12-0.22-0.29-0.430.590.460.030.130.630.090.380.640.360.020.430.57-0.220.61-0.080.350.11
-0.570.350.2-0.37-0.55-0.39-0.29-0.33-0.17-0.86-0.49-0.23-0.60.480.43-0.37-0.02-0.39-0.45-0.15-0.35-0.53-0.34-0.160.42
-0.11-0.34-0.31-0.180.310.41-0.43-0.33-0.260.140.0-0.13-0.12-0.06-0.89-0.16-0.22-0.1-0.43-0.230.33-0.130.34-0.75-0.6
0.470.540.270.860.180.020.59-0.17-0.260.490.31-0.240.490.040.090.650.56-0.070.210.73-0.020.470.240.25-0.18
0.840.180.020.650.480.350.46-0.860.140.490.630.130.86-0.21-0.350.690.520.430.260.620.270.820.390.31-0.55
0.740.21-0.220.30.240.770.03-0.490.00.310.63-0.080.6-0.06-0.170.530.520.170.040.50.740.580.190.56-0.39
0.13-0.16-0.2-0.13-0.2-0.170.13-0.23-0.13-0.240.13-0.080.2-0.10.1-0.03-0.110.190.34-0.13-0.060.180.170.210.25
0.980.390.280.740.440.220.63-0.6-0.120.490.860.60.20.13-0.010.890.670.470.210.770.160.990.330.47-0.34
0.180.570.660.16-0.35-0.030.090.48-0.060.04-0.21-0.06-0.10.13-0.010.30.41-0.09-0.550.36-0.080.230.130.04-0.23
-0.050.130.210.05-0.18-0.460.380.43-0.890.09-0.35-0.170.1-0.01-0.010.070.02-0.010.40.03-0.36-0.01-0.480.490.84
0.880.50.430.80.350.20.64-0.37-0.160.650.690.53-0.030.890.30.070.710.30.140.820.160.90.180.38-0.27
0.720.90.30.58-0.020.190.36-0.02-0.220.560.520.52-0.110.670.410.020.710.1-0.30.950.120.70.10.35-0.37
0.450.00.070.090.38-0.250.02-0.39-0.1-0.070.430.170.190.47-0.09-0.010.30.10.290.11-0.320.490.310.32-0.15
0.13-0.39-0.140.170.26-0.120.43-0.45-0.430.210.260.040.340.21-0.550.40.14-0.30.29-0.16-0.040.15-0.020.480.4
0.780.830.420.80.10.130.57-0.15-0.230.730.620.5-0.130.770.360.030.820.950.11-0.160.060.790.170.35-0.38
0.3-0.14-0.43-0.090.120.98-0.22-0.350.33-0.020.270.74-0.060.16-0.08-0.360.160.12-0.32-0.040.060.130.050.18-0.33
0.980.450.350.730.40.190.61-0.53-0.130.470.820.580.180.990.23-0.010.90.70.490.150.790.130.340.47-0.35
0.330.11-0.050.280.450.14-0.08-0.340.340.240.390.190.170.330.13-0.480.180.10.31-0.020.170.050.34-0.04-0.52
0.530.250.140.25-0.120.130.35-0.16-0.750.250.310.560.210.470.040.490.380.350.320.480.350.180.47-0.040.16
-0.39-0.23-0.14-0.29-0.25-0.480.110.42-0.6-0.18-0.55-0.390.25-0.34-0.230.84-0.27-0.37-0.150.4-0.38-0.33-0.35-0.520.16
Click cells to compare fundamentals

Lexicon Pharmaceuticals Account Relationship Matchups

Lexicon Pharmaceuticals fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets417.7M203.8M136.9M194.3M229.4M326.8M
Short Long Term Debt Total246.3M12.8M2.3M55.3M106.1M76.2M
Other Current Liab42.2M29.1M11.9M11.5M15.9M12.8M
Total Current Liabilities65.3M46.8M22.1M23.2M31.5M48.4M
Total Stockholder Equity(1.3B)156.4M(1.5B)(1.6B)93.1M97.8M
Property Plant And Equipment Net14.0M295K1.2M2.1M7.5M7.1M
Net Debt210.2M(113.5M)(61.8M)8.9M83.6M87.8M
Retained Earnings(1.3B)(1.4B)(1.5B)(1.6B)(1.8B)(1.7B)
Accounts Payable12.2M5.5M9.2M10.4M14.4M13.3M
Cash36.1M126.3M64.1M46.3M22.5M21.3M
Non Current Assets Total80.0M46.1M48.0M53.4M52.9M104.9M
Non Currrent Assets Other1.7M1.2M2.3M6.8M828K786.6K
Cash And Short Term Investments271.7M152.3M86.7M138.4M170.0M206.8M
Net Receivables56.5M395K14K28K1.0M959.5K
Common Stock Shares Outstanding116.7M110.8M145.7M165.7M221.1M232.2M
Short Term Investments235.5M26.0M22.7M92.0M147.6M137.0M
Liabilities And Stockholders Equity(1.0B)203.8M(1.5B)(1.5B)229.4M240.9M
Non Current Liabilities Total235.3M611K1.2M54.0M104.8M100.6M
Other Current Assets5.3M10.1M4.3M2.5M5.1M7.0M
Other Stockholder Equity(190K)1.6B1.6B1.7B1.9B941.0M
Total Liab300.6M47.4M23.3M77.2M136.3M149.0M
Property Plant And Equipment Gross14.0M295K6.0M12.9M12.0M11.4M
Total Current Assets337.8M157.7M88.9M140.9M176.5M221.8M
Accumulated Other Comprehensive Income84K(6K)(10K)(428K)31K32.6K
Short Term Debt11.0M12.2M1.1M1.3M1.2M1.1M
Other Assets285K(45K)1.2M136.9M157.4M165.3M
Long Term Debt231.6M243.9M234.2M48.6M99.5M77.2M
Property Plant Equipment14.0M295K1.2M2.1M1.9M1.8M
Other Liab29.9M55.4M35.8M23.3M26.8M43.1M
Treasury Stock(3.8M)(4.8M)(7.5M)(2.1M)(1.9M)(1.9M)
Net Tangible Assets52.8M111.8M69.1M72.6M65.3M67.6M
Retained Earnings Total Equity(1.3B)(1.4B)(1.5B)(1.6B)(1.4B)(1.5B)
Capital Surpluse1.5B1.6B1.6B1.7B2.0B1.5B
Inventory1.9M4.7M4.2M1.0381K362.0K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Lexicon Stock Analysis

When running Lexicon Pharmaceuticals' price analysis, check to measure Lexicon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexicon Pharmaceuticals is operating at the current time. Most of Lexicon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lexicon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexicon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lexicon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.